Therapeutic Efficacy of Melatonin in Patients with Coronavirus 2019: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The efficacy of melatonin in the treatment patients with coronavirus 2019 (COVID-19) is controversial. This review has summarized evidence on oral compared to placebo mild moderate COVID-19 infection. We searched four international online databases and all randomized clinical trials (RCTs) that investigated effects outcomes, including mortality, discharge time, O2 saturation (SaO2), c-reactive protein (CRP) levels infection, were included. standard random-effects model hybrid continuity correction was used pool risk ratio (RR), weighted mean difference (WMD), I2 index assess heterogeneity. A total 272 from five RCTs Our meta-analysis showed placebo, decreased time (WMD=-0.93 days; 95% confidence interval [CI]:-2.94 1.07, P=0.36; I2=56.78%) mortality (RR=0.72; CI:0.25 2.13, P=0.56; I2=0.0%) patients. Melatonin intake significantly increased SaO2 (WMD=1.38%; CI:0.09 2.68, P=0.04; I2=49.82%) CRP (WMD=-7.24 mg/l; CI:-11.28 -3.21, P<0.001) a sensitivity analysis. findings